MedTrace Logo

BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency

NCT07422389 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-02-20

No results posted yet for this study

Summary

The goal of this program is to provide patients with Limbal Stem Cell Deficiency access to the BRM421 eye drops.

Participants will:

* Use BRM421 two times a day for at least 12 weeks
* Visit the clinic monthly for checkups and tests

Conditions

  • Limbal Stem Cell Deficiency (LSCD)

Interventions

DRUG

BRM421 Ophthalmic Solution, 0.06%

Patients eligible to participate will receive 0.06% BRM421 Ophthalmic Solutions to be administered two times daily (BID, morning and bedtime) on the eligible eye(s). The administration will be at least 12 weeks. The investigator may continue the treatment beyond the 12 weeks based on clinical response. For patients scheduled for LSC transplant, treatment with BRM421 should start only after surgery.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07422389 on ClinicalTrials.gov